Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Oct;74(8):1199–1205. doi: 10.1038/bjc.1996.517

Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells.

C Courage 1, R Snowden 1, A Gescher 1
PMCID: PMC2075912  PMID: 8883405

Abstract

Staurosporine is a potent but non-specific kinase inhibitor. It has served as synthetic template for a variety of analogues, the indolocarbazoles, UCN-01 and CGP 41251, and the bisindolylmaleimides, Ro 31-8220 and GF 109203X, were investigated as growth inhibitors of human-derived A549 human lung adenocarcinoma cells. They were compared with respect to (1) effect on the cell cycle, (2) time dependency of growth arrest and (3) cytotoxic potency. Cells were exposed for 1, 2 and 4 days, or for 6, 12 and 24 h in the case of cycle-synchronised cells, to staurosporine analogues at concentrations at which they inhibited growth by 80% after 4 day exposure. Staurosporine and UCN-01 retarded cells in G0/1, and CGP 41251 appeared to inhibit cell growth without cell cycle specificity. Ro 31-8220 slowed progression of synchronised cells through the cycle; over a longer time period it induced a weak block in G2/M. GF 109203X induced potent G2/M arrest in synchronised cells. This was not so apparent in asynchronous cells, which by day 4 were slowed in G0/1 instead. Growth arrest induced by these inhibitors was more potent after incubation for 4 rather than 2 days. Incubation for 1 day followed by maintenance in drug-free medium for 3 days was sufficient to exert some cytostasis. The differences between cytotoxic and cytostatic concentrations, the former measured by release from cells of lactate dehydrogenase, were 15 000-fold for staurosporine, 300-fold for UCN-01, approximately 400-fold for CGP 41251, 25-fold for Ro 31-8220 and approximately 4-fold for GF 109203X. The results show that PKC-selective staurosporine analogues differ with respect to the mechanisms by which they interfere with the cell cycle. The necessity of long-term exposure for effective growth inhibition and the considerable margin between cytostatic and acute cytotoxic indolocarbazole concentrations are findings which might influence the planning and interpretation of clinical trials of these kinase inhibitors.

Full text

PDF
1199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe K., Yoshida M., Usui T., Horinouchi S., Beppu T. Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp Cell Res. 1991 Jan;192(1):122–127. doi: 10.1016/0014-4827(91)90166-r. [DOI] [PubMed] [Google Scholar]
  2. Akinaga S., Gomi K., Morimoto M., Tamaoki T., Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991 Sep 15;51(18):4888–4892. [PubMed] [Google Scholar]
  3. Akinaga S., Nomura K., Gomi K., Okabe M. Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. J Antibiot (Tokyo) 1993 Nov;46(11):1767–1771. doi: 10.7164/antibiotics.46.1767. [DOI] [PubMed] [Google Scholar]
  4. Akinaga S., Nomura K., Gomi K., Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol. 1994;33(4):273–280. doi: 10.1007/BF00685899. [DOI] [PubMed] [Google Scholar]
  5. Blobe G. C., Sachs C. W., Khan W. A., Fabbro D., Stabel S., Wetsel W. C., Obeid L. M., Fine R. L., Hannun Y. A. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. J Biol Chem. 1993 Jan 5;268(1):658–664. [PubMed] [Google Scholar]
  6. Courage C., Budworth J., Gescher A. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br J Cancer. 1995 Apr;71(4):697–704. doi: 10.1038/bjc.1995.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crissman H. A., Gadbois D. M., Tobey R. A., Bradbury E. M. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7580–7584. doi: 10.1073/pnas.88.17.7580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davis P. D., Elliott L. H., Harris W., Hill C. H., Hurst S. A., Keech E., Kumar M. K., Lawton G., Nixon J. S., Wilkinson S. E. Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity. J Med Chem. 1992 Mar 20;35(6):994–1001. doi: 10.1021/jm00084a004. [DOI] [PubMed] [Google Scholar]
  9. Gadbois D. M., Hamaguchi J. R., Swank R. A., Bradbury E. M. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem Biophys Res Commun. 1992 Apr 15;184(1):80–85. doi: 10.1016/0006-291x(92)91160-r. [DOI] [PubMed] [Google Scholar]
  10. Gong J., Traganos F., Darzynkiewicz Z. Staurosporine blocks cell progression through G1 between the cyclin D and cyclin E restriction points. Cancer Res. 1994 Jun 15;54(12):3136–3139. [PubMed] [Google Scholar]
  11. Hennipman A., van Oirschot B. A., Smits J., Rijksen G., Staal G. E. Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 1989 Feb 1;49(3):516–521. [PubMed] [Google Scholar]
  12. Ikegami Y., Yano S., Nakao K. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. Jpn J Pharmacol. 1996 Jan;70(1):65–72. doi: 10.1254/jjp.70.65. [DOI] [PubMed] [Google Scholar]
  13. Kawakami K., Futami H., Takahara J., Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun. 1996 Feb 27;219(3):778–783. doi: 10.1006/bbrc.1996.0310. [DOI] [PubMed] [Google Scholar]
  14. Meyer T., Regenass U., Fabbro D., Alteri E., Rösel J., Müller M., Caravatti G., Matter A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989 May 15;43(5):851–856. doi: 10.1002/ijc.2910430519. [DOI] [PubMed] [Google Scholar]
  15. Norbury C., Nurse P. Animal cell cycles and their control. Annu Rev Biochem. 1992;61:441–470. doi: 10.1146/annurev.bi.61.070192.002301. [DOI] [PubMed] [Google Scholar]
  16. O'Brian C. A., Ward N. E. Biology of the protein kinase C family. Cancer Metastasis Rev. 1989 Dec;8(3):199–214. doi: 10.1007/BF00047337. [DOI] [PubMed] [Google Scholar]
  17. Powis G. Signalling targets for anticancer drug development. Trends Pharmacol Sci. 1991 May;12(5):188–194. doi: 10.1016/0165-6147(91)90545-4. [DOI] [PubMed] [Google Scholar]
  18. Seynaeve C. M., Stetler-Stevenson M., Sebers S., Kaur G., Sausville E. A., Worland P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 1993 May 1;53(9):2081–2086. [PubMed] [Google Scholar]
  19. Stanwell C., Gescher A., Bradshaw T. D., Pettit G. R. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer. 1994 Feb 15;56(4):585–592. doi: 10.1002/ijc.2910560420. [DOI] [PubMed] [Google Scholar]
  20. Tamaoki T., Nakano H. Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology (N Y) 1990 Aug;8(8):732–735. doi: 10.1038/nbt0890-732. [DOI] [PubMed] [Google Scholar]
  21. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771–15781. [PubMed] [Google Scholar]
  22. Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer T., Müller M., Regenass U., Rihs G., Lydon N. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015–1027. doi: 10.1021/jm00033a019. [DOI] [PubMed] [Google Scholar]
  23. Utz I., Hofer S., Regenass U., Hilbe W., Thaler J., Grunicke H., Hofmann J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer. 1994 Apr 1;57(1):104–110. doi: 10.1002/ijc.2910570119. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES